Clinical Trials
3 trialsNCT00750698 2023-07-06
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Phase 2 Terminated
NCT00754312 2022-06-06
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
Syndax Pharmaceuticals
Phase 1 Terminated
NCT00866333 2019-10-22
ENGAGE-501
Syndax Pharmaceuticals
Phase 2 Terminated